Five year prostate-specific antigen outcomes after caesium prostate brachytherapy.
نویسندگان
چکیده
AIMS To report 5 year prostate-specific antigen outcomes in men undergoing prostate brachytherapy with caesium 131 at a single institution. MATERIALS AND METHODS All patients who underwent prostate brachytherapy with caesium 131 at our institution and had at least 24 months of follow-up were included in this study. The results are reported by risk group (low, intermediate and high) as well as by treatment received (monotherapy, combination therapy or trimodal therapy). The Phoenix definition (absolute nadir plus 2 ng/ml) was used to define biochemical freedom from disease (BFD). RESULTS Four hundred and eighty-five patients underwent prostate brachytherapy with caesium 131 at our institution and 367 patients had at least 24 months of follow-up and were included in this analysis. Using the Phoenix criteria, 5 year actuarial BFD was 96.0% for patients in the low-risk category, 92.7% for patients in the intermediate-risk category and 82.9% for patients in the high-risk category. By treatment category, 95.7% of men treated with monotherapy had BFD, 84.9% of men treated with combination therapy had BFD and 92.0% of men treated with trimodal therapy had BFD. CONCLUSIONS The present study showed that prostate brachytherapy with caesium 131 achieves excellent oncological outcomes at 5 years.
منابع مشابه
Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer
Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...
متن کاملPrediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
PURPOSE Prostate specific antigen velocity 2.0 ng/ml per year or greater in the year before prostate cancer diagnosis is associated with cancer specific survival following radical prostatectomy and radiation therapy. We evaluated the relationship between prediagnosis prostate specific antigen velocity and cancer progression following primary radiation therapy. MATERIALS AND METHODS We analyze...
متن کاملHistorical review of interstitial prostate brachytherapy
In the recent years, interstitial brachytherapy implantation has become the treatment of choice for early stage prostate cancer patients. Treatment of prostate cancer with radiation is traced back to 1909. Originally this treatment modality was very crude and could not gain much popularity till 1982. Advancements in radioactive source designs, introduction of new low energy radioactive sources,...
متن کاملProstate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
PURPOSE To evaluate the prognostic value of prostate-specific antigen nadir (nPSA) after high-dose-rate (HDR) brachytherapy in clinically non-metastatic high-risk prostate cancer patients. MATERIAL AND METHODS Data from 216 patients with high-risk or locally advanced prostate cancer who underwent HDR brachytherapy and external beam radiation therapy with long-term androgen deprivation therapy...
متن کاملTrajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer
BACKGROUND To describe trajectories of health-related quality of life (QoL), life satisfaction, and psychological adjustment for men with prostate cancer over the medium to long term and identify predictors of poorer outcomes using growth mixture models. METHODS One-thousand sixty-four (82.4% response) men diagnosed with prostate cancer were recruited close to diagnosis and assessed over a 72...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical oncology (Royal College of Radiologists (Great Britain))
دوره 26 12 شماره
صفحات -
تاریخ انتشار 2014